Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 57, Issue 11, 2018, Pages 1885-1895

  Choy, Ernest H S ^a   Calabrese, Leonard H ^b  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

IL 6; Rheumatoid arthritis; Sarilumab; Sirukumab; Tocilizumab

Indexed keywords

INTERLEUKIN 6; SARILUMAB; SIRUKUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ANXIETY DISORDER; CLINICAL TRIAL (TOPIC); COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; ENZYME INHIBITION; FATIGUE; HUMAN; HYPERALGESIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MOOD DISORDER; NEUROPHYSIOLOGY; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); ANTAGONISTS AND INHIBITORS; METABOLISM;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6;

EID: 85050267008     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex391     Document Type: Review

References (89)

1. Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care 2012;18:S295-302.
2. Singh JA, Saag KG, Bridges SL Jr et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
3. Radovits BJ, Fransen J, Al Shamma S et al. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res 2010;62:362-70.
4. Dougados M, Soubrier M, Antunez A et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014;73:62-8.
5. Sturgeon JA, Finan PH, Zautra AJ. Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways. Nat Rev Rheumatol 2016;12:532-42.
6. Tack BB. Self-reported fatigue in rheumatoid arthritis. A pilot study. Arthritis Care Res 1990;3:154-7.
7. Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA. Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum 2004;51:578-85.
8. Kojima M, Kojima T, Suzuki S et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:1018-24.
9. Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep 2008;10:258-64.
10. Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open 2015;1:e000019.
11. Orbai A-M, Bingham CO III. Patient reported outcomes in rheumatoid arthritis clinical trials. Curr Rheumatol Rep 2015;17:28.
12. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 2012;51:v3-11.
13. Rohleder N, Aringer M, Boentert M. Role of interleukin-6 in stress, sleep, and fatigue. Ann N Y Acad Sci 2012;1261:88-96.
14. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015;16:448-57.
15. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012;8:1237-47.
16. Yin T, Taga T, Tsang ML et al. Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J Immunol 1993;151:2555-61.
17. Yamasaki K, Taga T, Hirata Y et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988;241:825-8.
18. Narazaki M, Witthuhn BA, Yoshida K et al. Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc Natl Acad Sci USA 1994;91:2285-9.
19. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813:878-88.
20. Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014;10:720-7.
21. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95-8.
22. Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 2014;26:2-12.
23. O’Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002;109(Suppl):S121-31.
24. März P, Cheng J-G, Gadient RA et al. Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci USA 1998;95:3251-6.
25. Jostock T, Müllberg JG, Özbek S et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001;268:160-7.
26. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci 2012;122:143-59.
27. Eijsbouts AM, van den Hoogen FH, Laan RF et al. Hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:658-64.
28. Helal AM, Shahine EM, Hassan MM, Hashad DI, Moneim RA. Fatigue in rheumatoid arthritis and its relation to interleukin-6 serum level. Egypt Rheumatol 2012;34:153-7.
29. Schaible H-G. Nociceptive neurons detect cytokines in arthritis. Arthritis Res Ther 2014;16:470.
30. März P, Otten U, Rose-John S. Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur J Neurosci 1999;11:2995-3004.
31. Lee YC. Effect and treatment of chronic pain in inflammatory arthritis. Curr Rheumatol Rep 2013;15:300.
32. Heiberg T, Finset A, Uhlig T, Kvien TK. Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:191-5.
33. Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:924-7.
34. Cohen E, Lee YC. A mechanism-based approach to the management of osteoarthritis pain. Curr Osteoporos Rep 2015;13:399-406.
35. Zhou Y-Q, Liu Z, Liu Z-H et al. Interleukin-6: an emerging regulator of pathological pain. J Neuroinflammation 2016;13:141.
36. von Banchet GS, Kiehl M, Schaible H-G. Acute and long-term effects of IL-6 on cultured dorsal root ganglion neurones from adult rat. J Neurochem 2005;94:238-48.
37. Obreja O, Biasio W, Andratsch M et al. Fast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neurons. Brain 2005;128:1634-41.
38. Quarta S, Vogl C, Constantin CE et al. Genetic evidence for an essential role of neuronally expressed IL-6 signal transducer gp130 in the induction and maintenance of experimentally induced mechanical hypersensitivity in vivo and in vitro. Mol Pain 2011;7:73.
39. Brenn D, Richter F, Schaible H-G. Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain. Arthritis Rheum 2007;56:351-9.
40. Boettger MK, Leuchtweis J, Kümmel D et al. Differential effects of locally and systemically administered soluble glycoprotein 130 on pain and inflammation in experimental arthritis. Arthritis Res Ther 2010;12:R140.
41. Andratsch M, Mair N, Constantin CE et al. A key role for gp130 expressed on peripheral sensory nerves in pathological pain. J Neurosci 2009;29:13473-83.
42. Vazquez E, Kahlenbach J, Segond von Banchet G et al. Spinal interleukin-6 is an amplifier of arthritic pain in the rat. Arthritis Rheum 2012;64:2233-42.
43. Genovese MC, Fleischmann R, Kivitz AJ et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis. Rheumatol 2015;67:1424-37.
44. Actemra [package insert]. South San Francisco, CA: Genentech, 2016.
45. Lazzerini PE, Capecchi PL, Guidelli GM et al. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date. Drug Des Devel Ther 2016;10:3083-98.
46. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011;63:S240-52.
47. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
48. Kremer JM, Blanco R, Brzosko M et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
49. Fleischmann RM, Halland A-M, Brzosko M et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol 2013;40:113-26.
50. Burmester GR, Feist E, Kellner H et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755-9.
51. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
52. Strand V, Kosinski M, Chen C-I et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther 2016;18:198.
53. Strand V, Reaney M, Chen C-I et al. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. RMD Open 2017;3:e000416.
54. Burmester GR, Lin Y, Patel R et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 2017;76:840-7.
55. Aletaha D, Bingham CO, III, Tanaka Y et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet 2017;389:1206-17.
56. Hewlett S, Cockshott Z, Byron M et al. Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005;53:697-702.
57. Townes SV, Furst DE, Thenkondar A. The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation. Open Access Rheumatol 2012;4:87-92.
58. Nikolaus S, Bode C, Taal E, van de Laar MA. Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res 2013;65:1128-46.
59. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351-62.
60. Silverman MN, Pearce BD, Biron CA, Miller AH. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol 2005;18:41-78.
61. Silverman MN, Sternberg EM. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci 2012;1261:55-63.
62. Papadopoulos AS, Cleare AJ. Hypothalamic-pituitary-adrenal axis dysfunction in chronic fatigue syndrome. Nat Rev Endocrinol 2011;8:2232.
63. Du X, Pang TY. Is dysregulation of the HPA-axis a core pathophysiology mediating co-morbid depression in neurodegenerative diseases? Front Psychiatry 2015;6:32.
64. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002;53:865-71.
65. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenalaxis in humans. J Clin Endocrinol Metab 1993;77:1690-4.
66. Walker JG, Littlejohn GO, McMurray NE, Cutolo M. Stress system response and rheumatoid arthritis: a multilevel approach. Rheumatology 1999;38:1050-7.
67. Vgontzas AN, Papanicolaou DA, Bixler EO et al. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 1999;84:2603-7.
68. Späth-Schwalbe E, Hansen K, Schmidt F et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998;83:1573-9.
69. Vgontzas AN, Bixler EO, Lin H-M et al. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 2005;12:131-40.
70. Crofford LJ, Kalogeras KT, Mastorakos G et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997;82:1279-83.
71. Cella D, Yount S, Sorensen M et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811-9.
72. Almeida C, Choy EH, Hewlett S et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev 2016;6;CD008334.
73. Fragiadaki K, Tektonidou MG, Konsta M, Chrousos GP, Sfikakis PP. Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J Rheumatol 2012;39:60-2.
74. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50.
75. Murphy LB, Sacks JJ, Brady TJ, Hootman JM, Chapman DP. Anxiety and depression among US adults with arthritis: prevalence and correlates. Arthritis Care Res 2012;64:968-76.
76. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology 2013;52:2136-48.
77. Rathbun AM, Reed GW, Harrold LR. The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review. Rheumatology 2013;52:1785-94.
78. Hodes GE, Pfau ML, Leboeuf M et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci USA 2014;111:16136-41.
79. Virtanen M, Shipley MJ, Batty GD et al. Interleukin-6 as a predictor of symptom resolution in psychological distress: a cohort study. Psychol Med 2015;45:2137-44.
80. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 2015;49:206-15.
81. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-57.
82. Maes M, Bosmans E, De Jongh R et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997;9:853-8.
83. Hodes GE, Ménard C, Russo SJ. Integrating interleukin-6 into depression diagnosis and treatment. Neurobiol Stress 2016;4:15-22.
84. Bull SJ, Huezo-Diaz P, Binder EB et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-α and ribavirin treatment. Mol Psychiatry 2009;14:1095-104.
85. Bonaccorso S, Puzella A, Marino V et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001;105:45-55.
86. Girotti M, Donegan JJ, Morilak DA. Influence of hypothalamic IL-6/gp130 receptor signaling on the HPA axis response to chronic stress. Psychoneuroendocrinology 2013;38:1158-69.
87. Matcham F, Norton S, Steer S, Hotopf M. Usefulness of the SF-36 Health Survey in screening for depressive and anxiety disorders in rheumatoid arthritis. BMC Musculoskelet Disord 2016;17:224.
88. Louati K, Berenbaum F. Fatigue in chronic inflammation - a link to pain pathways. Arthritis Res Ther 2015;17:254.
89. Morand EF, Leech M. Hypothalamic-pituitary-adrenal axis regulation of inflammation in rheumatoid arthritis. Immunol Cell Biol 2001;79:395-9.